Management Tracks: Evox, Phoenix Tissue Repair, Artax, Nucleix, IsoPlexis, Centogene, Immunicum, CohBar and CorMedix
Evox Therapeutics Ltd. said Paul Carter will succeed Edwin Moses as non-executive chairman. Carter was EVP, chief commercial officer of Gilead Sciences Inc. (NASDAQ:GILD). The exosome therapeutics company partnered with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) in March (see “Takeda Pursuing Exosome Therapies Through Evox Deal”).
BridgeBio Pharma Inc. (NASDAQ:BBIO) subsidiary Phoenix Tissue Repair Inc. appointed Sanuj Ravindran as chairman and hired Deborah Ramsdell as COO and Hal Landy as CMO. Ravindran is president and CEO of PellePharm Inc., another subsidiary of the genetic diseases company. Ramsdell is biotechnology executive consultant as well as consultant president and CEO at Valerion Therapeutics LLC and Wings Therapeutics. Landy is CMO at Valerion and Wings...